MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00520-026-10709-8

Медицинская библиотека · Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026

Weight change and impact on prognosis in patients with advanced non-small cell lung cancer with concomitant diabetes mellitus treated with sglt2 inhibitors.

Morikawa Noboru, Naito Tateaki, Okawa Yuta, Matsuda Suguru, Morita Meiko, Sekikawa Motoki, Doshita Kosei, Yabe Michitoshi, Kodama Hiroaki, Miura Keita, Iida Yuko, Mamesaya Nobuaki, Kobayashi Haruki, Ko Ryo, Ono Akira, Kenmotsu Hirotsugu, Murakami Haruyasu, Takahashi Toshiaki

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are commonly used to manage diabetes and are known to cause weight loss. This study aimed to clarify whether SGLT2i-induced weight loss influences survival or toxicity during systemic therapy in patients with advanced non-small cell lung cancer (NSCLC) and comorbid diabetes.

METHODS

We conducted a retrospective analysis of patients with advanced NSCLC and diabetes who received first-line systemic therapy. Patients with an Eastern Cooperative Oncology Group performance status (PS) ≥ 3, driver mutations, interstitial lung disease, untreated diabetes, or missing data were excluded. We compared weight changes, progression-free survival (PFS), overall survival (OS), and adverse events between patients with and without SGLT2i. We defined cachexia as either 5% or more body-weight loss within six months prior to the initiation of lung cancer treatment or weight loss greater than 2% and a body-mass index (BMI) of less than 20 kg/m2.

RESULTS

Eighteen patients (21.9%) out of 82 received SGLT2i for diabetes. There was no difference in the incidence of cachexia between the two groups (66.7% vs. 46.9%, p = 0.184), despite significant weight loss in the SGLT2 group compared to the non-SGLT2 group (median - 5.8% vs. - 3.4%, p = 0.039). No significant differences were observed in progression-free survival (PFS) (median 6.2 vs. 4.1 months, p = 0.512) or overall survival (OS) (median 11.9 vs. 14.6 months, p = 0.583). Grade ≥ 3 adverse events occurred in 11.1% of patients in the SGLT2i group and 31.2% of patients in the non-SGLT2i group (P = 0.132). There were no cases of diabetic ketoacidosis or urinary tract infections.

CONCLUSION

SGLT2 inhibitors were associated with weight loss and were not associated with worse survival or increased toxicity in this limited retrospective cohort.

Для цитирования: Morikawa Noboru, Naito Tateaki, Okawa Yuta, Matsuda Suguru, Morita Meiko, Sekikawa Motoki, Doshita Kosei, Yabe Michitoshi, Kodama Hiroaki, Miura Keita, Iida Yuko, Mamesaya Nobuaki, Kobayashi Haruki, Ko Ryo, Ono Akira, Kenmotsu Hirotsugu, Murakami Haruyasu, Takahashi Toshiaki. Weight change and impact on prognosis in patients with advanced non-small cell lung cancer with concomitant diabetes mellitus treated with sglt2 inhibitors.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2026. DOI: 10.1007/s00520-026-10709-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.